AAPL   322.70 (+0.26%)
MSFT   184.62 (+0.98%)
FB   231.53 (-0.16%)
GOOGL   1,438.93 (+0.28%)
AMZN   2,472.41 (+0.06%)
NVDA   351.88 (-0.11%)
CGC   16.12 (-2.18%)
MU   46.74 (+0.86%)
GE   7.02 (+3.85%)
TSLA   884.39 (-1.53%)
AMD   53.39 (-0.47%)
T   30.95 (+0.06%)
F   5.90 (+0.51%)
GILD   73.23 (-2.57%)
NFLX   427.01 (+0.26%)
BAC   24.77 (+0.65%)
BA   153.17 (+1.18%)
AAPL   322.70 (+0.26%)
MSFT   184.62 (+0.98%)
FB   231.53 (-0.16%)
GOOGL   1,438.93 (+0.28%)
AMZN   2,472.41 (+0.06%)
NVDA   351.88 (-0.11%)
CGC   16.12 (-2.18%)
MU   46.74 (+0.86%)
GE   7.02 (+3.85%)
TSLA   884.39 (-1.53%)
AMD   53.39 (-0.47%)
T   30.95 (+0.06%)
F   5.90 (+0.51%)
GILD   73.23 (-2.57%)
NFLX   427.01 (+0.26%)
BAC   24.77 (+0.65%)
BA   153.17 (+1.18%)
AAPL   322.70 (+0.26%)
MSFT   184.62 (+0.98%)
FB   231.53 (-0.16%)
GOOGL   1,438.93 (+0.28%)
AMZN   2,472.41 (+0.06%)
NVDA   351.88 (-0.11%)
CGC   16.12 (-2.18%)
MU   46.74 (+0.86%)
GE   7.02 (+3.85%)
TSLA   884.39 (-1.53%)
AMD   53.39 (-0.47%)
T   30.95 (+0.06%)
F   5.90 (+0.51%)
GILD   73.23 (-2.57%)
NFLX   427.01 (+0.26%)
BAC   24.77 (+0.65%)
BA   153.17 (+1.18%)
AAPL   322.70 (+0.26%)
MSFT   184.62 (+0.98%)
FB   231.53 (-0.16%)
GOOGL   1,438.93 (+0.28%)
AMZN   2,472.41 (+0.06%)
NVDA   351.88 (-0.11%)
CGC   16.12 (-2.18%)
MU   46.74 (+0.86%)
GE   7.02 (+3.85%)
TSLA   884.39 (-1.53%)
AMD   53.39 (-0.47%)
T   30.95 (+0.06%)
F   5.90 (+0.51%)
GILD   73.23 (-2.57%)
NFLX   427.01 (+0.26%)
BAC   24.77 (+0.65%)
BA   153.17 (+1.18%)
Log in

OTCMKTS:CYYNFCynata Therapeutics Stock Price, Forecast & News

$0.47
0.00 (0.00 %)
(As of 05/22/2020)
Add
Compare
Today's Range
$0.47
Now: $0.47
$0.47
50-Day Range
$0.36
MA: $0.44
$0.50
52-Week Range
$0.35
Now: $0.47
$1.25
Volume20,000 shs
Average Volume4,518 shs
Market Capitalization$44.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Sanitary paper products
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYYNF
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$44.96 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CYYNF News and Ratings via Email

Sign-up to receive the latest news and ratings for CYYNF and its competitors with MarketBeat's FREE daily newsletter.

Cynata Therapeutics (OTCMKTS:CYYNF) Frequently Asked Questions

How has Cynata Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Cynata Therapeutics' stock was trading at $0.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYYNF stock has decreased by 37.3% and is now trading at $0.47. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cynata Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cynata Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cynata Therapeutics.

Has Cynata Therapeutics been receiving favorable news coverage?

News coverage about CYYNF stock has been trending positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cynata Therapeutics earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutCynata Therapeutics.

Who are some of Cynata Therapeutics' key competitors?

Who are Cynata Therapeutics' key executives?

Cynata Therapeutics' management team includes the following people:
  • Dr. Ross Alexander MacDonald Ph.D., MD, CEO & Exec. Director (Age 61)
  • Mr. Peter G. Webse B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. & Non-Exec. Director (Age 56)
  • Dr. Kilian Kelly, VP of Product Devel.

What is Cynata Therapeutics' stock symbol?

Cynata Therapeutics trades on the OTCMKTS under the ticker symbol "CYYNF."

How do I buy shares of Cynata Therapeutics?

Shares of CYYNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cynata Therapeutics' stock price today?

One share of CYYNF stock can currently be purchased for approximately $0.47.

How big of a company is Cynata Therapeutics?

Cynata Therapeutics has a market capitalization of $44.96 million.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.